Jun 9, 2011 by Brian Orelli, PhDXOMA Breaks Bad News to InvestorsXOMA 052 continues to be a disaster in diabetes.
Jun 9, 2011 by Brian Orelli, PhDGet Out of Here! $0.5 Million to License a Drug? Somaxon licenses rights to Silenor in Canada, South America, and Africa to Paladin.
Jun 9, 2011 by Brian Orelli, PhDIt's a Numbers Game With VertexHow many patients can its cystic fibrosis program treat?
Jun 8, 2011 by Brian Orelli, PhD11 Incredible Dividend Stocks: Abbott LabsA health-care conglomerate with growth potential.
Jun 8, 2011 by Brian Orelli, PhDBlockbuster Drug-Like Profits, No FDA RequiredPfizer keeps the cuts coming.
Jun 7, 2011 by Brian Orelli, PhDSometimes a Partnership Feels PersonalMerck and Roche hook up for a diagnostic drug deal.
Jun 6, 2011 by Brian Orelli, PhDBig Pharma Tackles Lung Cancer; Biotech Helping, TooA big underserved market.
Jun 3, 2011 by Brian Orelli, PhDTag-Teaming Melanoma for Fun and ProfitBristol-Myers Squibb and Roche hook up.
Jun 2, 2011 by Brian Orelli, PhDThe Drug Works, But by How Much?Aastrom's investors need to check the data before getting too excited.
Jun 1, 2011 by Brian Orelli, PhDNot All "Regulatory Updates" Are the Good KindOrexigen gives an update; investors update their holdings.
May 31, 2011 by Brian Orelli, PhDThe Biggest Gift Biotechs Can Give to InvestorsDilution-free financing.
May 31, 2011 by Brian Orelli, PhDDown! Up! Which Way Will Optimer Go Next?Long-term prospects look good.
May 31, 2011 by Brian Orelli, PhDPay Attention, Biotech InvestorsCompetitors and partners can't be ignored.
May 31, 2011 by Brian Orelli, PhDToo Many Drugs, Too Little CashAVEO seals a deal with Johnson & Johnson.
May 31, 2011 by Brian Orelli, PhD5 Biotechs With Upcoming Clinical Trial Results The other binary event.
May 27, 2011 by Brian Orelli, PhDAIM-HIGH? These Drugmakers Better Duck.A government study hurts Abbott and Merck
May 27, 2011 by Brian Orelli, PhDDon't Believe the Obesity HypeMeta-analysis isn't going to help Arena Pharmaceuticals.
